Welcome to our dedicated page for Staar Surg SEC filings (Ticker: STAA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
STAAR Surgical Company filings document the regulatory record for a NASDAQ-listed ophthalmic device company focused on phakic IOLs and the EVO family of Implantable Collamer® Lenses. Its reports and exhibits cover operating results, preliminary sales disclosures, shareholder letters, product and market commentary, and clinical or regulatory matters tied to lens-based vision correction.
Recent filings also address proxy and governance disclosure, shareholder voting matters, board and committee composition, director independence, executive appointments and separation arrangements, material agreements, capital-structure disclosure for common stock, and the termination of a previously disclosed merger agreement.
STAAR Surgical Company appointed Warren Foust and Deborah Andrews as Interim Co‑Chief Executive Officers effective February 1, 2026, following the previously announced departure of CEO Stephen C. Farrell. The Board has formed a search committee and begun a global search for a permanent Chief Executive Officer.
Foust, currently President and Chief Operating Officer, and Andrews, currently Chief Financial Officer, will retain their existing roles while serving as Interim Co‑CEOs. Each will receive restricted stock units with a grant date fair value of $375,000, scheduled to vest on August 1, 2026 or an earlier date under the grant terms.
The company entered into a letter agreement with Foust setting his Interim Co‑CEO term through the earlier of August 1, 2026 or public announcement of a new CEO and clarifying when his resignation or termination would trigger “Good Reason” treatment and enhanced vesting and severance benefits under his existing agreements.
STAAR Surgical director Richard T. LeBuhn filed an initial statement of beneficial ownership of securities. He reports beneficial ownership of 21,268 shares of common stock held directly. He also reports 18 shares held in three separate accounts for his daughters, over which he has voting and dispositive control. In addition, 844 shares are held by an irrevocable trust for his daughter; he is not the trustee, has no voting or dispositive power over those securities, and disclaims beneficial ownership except to the extent of his pecuniary interest. The filing notes that Mr. LeBuhn was appointed to the company’s Board of Directors on January 14, 2026.
STAAR Surgical and major shareholder Broadwood Partners entered a cooperation agreement that reshapes the company’s board and clarifies the Broadwood group’s status. Broadwood Partners and Broadwood Capital report beneficial ownership of 15,453,629 shares each, or about 31.1% of the 49,741,953 shares outstanding as of October 31, 2025. Neal C. Bradsher may be deemed to beneficially own 15,479,529 shares, also about 31.1% of the class.
The agreement leads to two directors resigning, three new directors being appointed (including Bradsher and Richard T. LeBuhn) and nominated for election at the 2026 annual meeting. Broadwood agrees not to request a special shareholder meeting, including to remove directors, until June 18, 2026, and both sides provide mutual releases and non‑disparagement commitments.
STAAR Surgical Co received an updated ownership filing from a group of investment entities connected to Yunqi and HS Group. The largest reported position is 3,257,130 shares of common stock, representing 6.5% of the class, beneficially owned by Yunqi Capital Limited, Yunqi Capital Cayman Limited, Christopher Min Fang Wang, and related entities. Other entities in the group, including Yunqi Path Capital Master Fund and Yunqi China Special Investment A, report additional share holdings, with Yunqi Path Capital Master Fund alone reporting 2,575,061 shares, or 5.2% of the class. The amendment also notes that on January 14, 2026, STAAR Surgical entered into a cooperation agreement with Broadwood Partners, L.P., under which Christopher Min Fang Wang was appointed to the company’s Board of Directors effective that same date.
STAAR Surgical Company reported several corporate governance changes centered on its Board of Directors. Effective January 15, 2026, the Board elected Neal C. Bradsher as Board Chair. Bradsher is the founder and president of Broadwood Capital, Inc., whose affiliate Broadwood Partners, L.P. is currently the company’s largest stockholder.
The Board restructured its three standing committees so that the Audit, Compensation, and Nominating and Governance committees are each composed entirely of independent directors. STAAR notified NASDAQ that it has regained compliance with the Audit Committee independence requirements under NASDAQ Listing Rule 5605, so it is no longer operating under a cure period.
The Board also created two new committees: a Search Committee to help guide decisions on company leadership, including identifying a successor to the Chief Executive Officer, and an Insight and Engagement Committee to strengthen engagement with management, stakeholders, and industry experts. Non-employee directors, including the new Board Chair, will be eligible for compensation for these roles under the existing director compensation program.
STAAR Surgical Company entered a cooperation agreement with major stockholder Broadwood Partners, L.P., leading to significant board and leadership changes. The Board size increased from six to seven directors, two directors, including CEO and director Stephen C. Farrell and director Elizabeth Yeu, MD, resigned from the Board, and three new directors, Neal C. Bradsher, Richard T. LeBuhn and Christopher Min Fang Wang, were appointed and will be nominated for election at the 2026 annual meeting. Mr. Farrell will step down as Chief Executive Officer effective January 31, 2026, or earlier as determined by the Board, and will provide consulting services for one year at $45,000 per month, with severance and continued equity treatment as outlined in his agreements. Following Dr. Yeu’s resignation, the Company no longer meets NASDAQ’s requirement for three independent audit committee members and has notified NASDAQ of its intent to use the cure period to regain compliance. Broadwood agreed not to seek a special meeting of stockholders until June 18, 2026, and the parties exchanged customary non-disparagement and releases.
STAAR Surgical director Wei Jiang reported the vesting and conversion of restricted stock units into common shares. On January 12, 2026, 20,967 restricted stock units granted on May 12, 2025 vested and were converted into 20,967 shares of STAAR Surgical common stock at an exercise price of $0 per share. These units were the final third of an award that vested in three equal installments on August 12, 2025, November 12, 2025, and January 12, 2026. Following this transaction, Jiang directly beneficially owned 66,444 shares of STAAR Surgical common stock.
Broadwood Partners, L.P., a 10% owner of STAAR Surgical, reported buying 27,485 shares of common stock on January 9, 2026 at a weighted average price of $22.0534 per share, bringing its directly owned stake to 15,453,629 shares.
These shares are held by Broadwood Partners and may be deemed indirectly beneficially owned by Broadwood Capital, Inc. and its president, Neal C. Bradsher, who also directly owns 25,900 shares of STAAR Surgical common stock.
Broadwood Partners, L.P., a 10% owner of STAAR Surgical Co. (STAA), reported open‑market purchases of the company’s common stock in early January 2026. Broadwood Partners bought 186,946 shares at a weighted average price of $21.0111 and 150,000 shares at $22.3756 on January 6, followed by 66,467 shares at $22.0004 on January 7 and 3,240 shares at $21.9389 on January 8. After these transactions, Broadwood Partners reported holding 15,426,144 shares of STAAR Surgical common stock. A separate holding of 25,900 STAAR Surgical shares is reported as being directly owned by Neal C. Bradsher. The filing notes that Broadwood Capital, Inc. and Neal C. Bradsher may be deemed indirect beneficial owners through their roles with Broadwood Partners, but each disclaims beneficial ownership except to the extent of any pecuniary interest.
STAAR Surgical’s major shareholders updated their ownership report in this amended Schedule 13D. A group of Yunqi- and HS-branded entities, together with individual investor Christopher Min Fang Wang, disclose beneficial ownership of STAAR Surgical common stock based on 49,751,953 shares outstanding as of October 31, 2025.
Yunqi Path Capital Master Fund reports beneficial ownership of 2,575,061 shares, representing 5.2% of the company. Yunqi Capital Limited, Yunqi Capital Cayman Limited and Mr. Wang each report beneficial ownership of 3,257,130 shares, or 6.5% of the outstanding stock. Yunqi China Special Investment A and several HS Group entities each report beneficial ownership of 682,069 shares, or 1.4%.
The filing states that share purchases, totaling up to tens of millions of dollars across the reporting entities, were funded from working capital, with no dedicated borrowing other than ordinary-course working capital. On January 8, 2026, the reporting persons also entered into a Joint Filing Agreement to coordinate their Schedule 13D filings.